Immuneering Corporation (IMRX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Immuneering Corporation  (NASDAQ: IMRX)


Immuneering's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Immuneering's ROI in the second quarter of 2026?
Immuneering Corporation recorded a cumulative net loss of $-57 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -26.71%.

Within the Healthcare sector 353 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3420 to 3507.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 361.8 % 212.27 % 104.76 % 14.89 % -47.85 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 194 210 222 232 33
Return On Investment (TTM) -26.71 % -31.26 % -42.1 % -70.3 % -133.82 %
IMRX's Overall Ranking # 3507 # 3420 # 3306 # 3558 # 3383
Seq. Investment Change TTM 23.11 % 30.87 % 49.69 % 91.47 % -16.75 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -57 -54 -56 -62 -62

IMRX Company Profile >> Back to IMRX Roi Comparisons >> See Annual IMRX Return On Investment



Return On Investment IMRX's Ranking
Within: No.
Industry # 135
Sector # 354
Overall # 3507

Return On Investment Statistics
High Average Low
-26.71 %
-55.79 %
-133.82 %
(Jun 30 2026)   (Jun 30 2025)



  News about Immuneering Corporation Return on Investment ROI

Amid Financial Hurdles, Immuneering Pursues Hope in the Fight Against Pancreatic Cancer,

December 17, 2024

Immuneering s Bold Move in Pancreatic Cancer Treatment Amid Financial ChallengesIn a high-stakes environment where the pharmaceutical industry is often fraught with both promise and peril, Immuneering Corporation s recent announcements have sparked a wave of enthusiasm and concern. The Cambridge-based biotech firm is on the precipice of critical data presentations and has secured a significant regulatory designation, yet it grapples with noteworthy financial struggles.Immuneering has revealed plans to present data from three arms of its ongoing Phase 2a trial of its drug candidate, IMM-1-104, slated for early January 2025. This trial, aimed at assessing the efficacy of IMM-1-104 in treating pancreatic cancer, has garnered considerable attention—especially following the company’s recent achievement: receiving Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). This designation serves as a recognition of the urgent need for new therapeutics targeting pancreatic cancer, a condition notorious for its late-stage diagnosis and dismal survival rates. With pancreatic cancer being the fifth leading cause of cancer-related deaths in the U.S. any potential advancement holds significant promise for both patients and investors.





Financial Statements
Immuneering's II. Quarter Investments $ 194 Millions IMRX's Balance sheet
Immuneering's II. Quarter Income $ -17 Millions Quarterly IMRX's Income Statement
IMRX's Income by Division See IMRX's Income by Division


IMRX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 222 45 95 114 161
Y / Y Investment Growth 390.84 % -52.28 % -17.12 % -29.03 % -
Net Income in Millions -56 -61 -53 -51 -34
Y / Y Net Income Growth - - - - -
Annual Return On Investment -25.25 % -135.01 % -56.44 % -44.19 % -20.82 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
IMRX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for IMRX's Competitors
Subscribers only: Roi for Immuneering's Suppliers
Subscribers only: Return On Investment for IMRX's Customers

Other Ratios
IMRX's Roa IMRX's Inventory Turnover Ratio IMRX's Growth Rates IMRX's Dividend Statistics
IMRX's Profitability Ratios IMRX's Asset Turnover Ratio IMRX's Dividend Growth
IMRX's Roe IMRX's Valuation Ratios IMRX's Financial Strength Ratios IMRX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-08T15:11:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.